Rinsho Shinkeigaku (Clinical Neurology)

The 50th Annual Meeting of the Japanese Society of Neurology

Early diagnostic biomarker for Alzheimer's disease in now and future

Katsuya Urakami, M.D. and Miyoko Taniguchi, Ph.D.

Department of Biological Regulation, Faculty of Medicine, Tottori University

Alzheimer's disease is thought to be "common disease". It is expected that new biological diagnostic marker will be discovered for Alzheimer's disease. There are two roles in diagnostic biomarker for AD.; one is a screening and the other one is to help definite diagnosis for AD. Simple screening method using touch panel type computer (Forgetfulness consultation program) is most useful of screening tools and phosphorylated tau protein in cerebrospinal fluid is highly appreciated as a diagnostic biomarker to help definite diagnosis. Serum WGA binding transferrin in AD is significantly higher than that in controls and high levels of it proceed increased levels of amyloid beta protein. Serum WGA binding transferrin may be useful for early diagnostic biomarker in serum.
Full Text of this Article in Japanese PDF (468K)

(CLINICA NEUROL, 49: 841|844, 2009)
key words: Dementia, biomarker, phosphorylated tau protein, Forgetfulness consultation program, WGA binding trasferrin

(Received: 21-May-09)